[1] FUTURE Ⅱ Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med, 2007, 356(19):1915-1927. [2] FUTURE Ⅱ Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis,2007, 196(10):1438-1446. [3] Stanley M. Prophylactic HPV vaccines. J Clin Pathol,2007, 60(9):961-965. [4] Villa LL. Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. Int J Infect Dis, 2007, 11（Suppl 2）: S17-S25. [5] Morris SK, Nguyen CK. The human papillomavirus vaccine in Canada. Can J Public Health, 2008, 99（2）:114-116. [6] Vandepapeliere P, Barrasso R, Meijer CJ, Walboomers JM, Wetterndorff M, Stanberry LR, et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 2005;192:20 99-107. [7]. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, et al. Decline in varicella-zoster virus (VZV)-specific cellmediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis 2003;188:13 36-44. [8]. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JK. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005;191:200 2-7. [9]. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE,Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:22;71-84. [10] John W. Gnann, Jr. Vaccination to Prevent Herpes Zoster in Older Adults . The Journal of Pain, 2008, 9(1 ):S31-S36. [11] Peng-jun Lua, Gary L. Eulera, Aisha O. Jumaanb et al. Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: Uptake of the first new vaccine to target seniors. Vaccine 27 (2009) 882–887. [12]　中国科学院生命科学和医学学部. 关于我国艾滋病疫苗研发策略的建议. 中国科学院院刊, 2006, 21: 391 - 394. [13]　McMichael AJ. H IV vaccines. Annul Rev Immunol, 2006,24: 227 - 255. [14] Scheid JF, Mouquet H, Feldhahn N, Seaman MS et al. Broad diversity of neutralizing antibodies isolated from memory B cNature. 2009 Apr 2;458(7238):584-5. [15] Us D. Herpes simp lex virus vaccine studies: from past to p resent. Mikrobiyol Bul, 2006, 40 (4) : 413-433。ells in HIV-infected individuals. [16] Parsania M, Bamdad T, Hassan ZM, et al. Evaluation of apoptotic and anti-apoptotic genes on efficacy of DNA vaccine encoding glycoprotein B of Herpes Simplex Virus type 1. Immunol Lett. 2009 Dec 21. [Epub ahead of print]. [17] Bernstein DI, Farley N, Bravo FJ, et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine. 2009 Oct 24. [Epub ahead of print].